GSK (GSK) Reports Strong Q2 Beat and Unveils Accelerate Growth Plan
Key Takeaways
- Revenue beat: GSK posted second-quarter turnover of £8.41 billion, exceeding the analyst consensus of £8.24 billion and rising 5% at constant exchange rates (CER).
- Profit outperformance: Core operating profit reached £2.80 billion, ahead of the £2.68 billion consensus, while core earnings per share (EPS) of 50.5 pence comfortably beat the 47.1 pence forecast.
- Specialty Medicines lead the way: The division grew 14% to £3.8 billion, driven by double-digit gains in Oncology, HIV, and Respiratory, Immunology & Inflammation.
- Vaccines momentum continues: Sales rose 8% to £2.3 billion, with Arexvy more than doubling and Shingrix delivering £888 million, edging past consensus.
- £1.9 billion cost-savings programme unveiled: The three-year "Accelerate Growth" plan targets annual savings by 2029, with most funds reinvested into the late-stage pipeline.
- Shares hit a three-month high: GSK stock surged as much as 6% in London following the release, reflecting broad investor approval of the results and strategic update.
Why This Quarter Carries Extra Weight
GSK's second-quarter report carried extra weight because it coincided with the company's "Accelerate Growth" strategy event, where CEO Luke Miels laid out the long-term vision for the drugmaker. Investors have been closely monitoring GSK's transition from a diversified pharmaceutical company into a focused biopharma player centered on specialty medicines and vaccines. The quarter also arrived against the backdrop of a looming patent cliff: dolutegravir, the backbone of GSK's HIV franchise, begins losing US patent protection in 2028. How well the company can offset that revenue erosion through pipeline acceleration and margin discipline is the central question for shareholders, making this quarter's results—and the accompanying restructuring announcement—especially significant. I also checked this using Tickeron’s AI Screener to see how GSK compares to others in the industry.
Breaking Down the Reported Results
GSK reported second-quarter 2026 turnover of £8.41 billion, a 5% increase at constant exchange rates, surpassing the company-compiled consensus of £8.24 billion. Core operating profit came in at £2.80 billion, comfortably above the £2.68 billion consensus, while core EPS of 50.5 pence beat the 47.1 pence estimate by approximately 7%.
Specialty Medicines was the standout performer, generating £3.8 billion in sales—up 14% year-on-year. Within the division, Respiratory, Immunology & Inflammation grew 19%, Oncology advanced 17%, and HIV rose 10%. The long-acting injectable HIV treatments Cabenuva and Apretude posted increases of 33% and 39%, respectively, while oncology assets Jemperli and Blenrep also delivered strong double-digit growth.
Vaccines revenue climbed 8% to £2.3 billion. Shingrix, the shingles vaccine, generated £888 million, slightly ahead of the consensus estimate of £867.8 million. Arexvy, the respiratory syncytial virus (RSV) vaccine, more than doubled its sales compared to the prior-year period. Meningitis vaccine sales rose 21%.
General Medicines remained the weak spot, with sales declining 9% to £2.3 billion, missing the £2.42 billion consensus. Trelegy, the respiratory inhaler, saw revenue dip 7%, reflecting ongoing pressures from generic competition and pricing headwinds in mature markets.
On a statutory (reported) basis, total operating profit fell 75%, weighed down by a £1.3 billion impairment charge tied primarily to camlipixant, the investigational chronic cough treatment that failed to meet endpoints in late-stage trials. GSK declared a second-quarter dividend of 17 pence per share and indicated a 70 pence full-year payout is expected.
Management reaffirmed full-year 2026 guidance, now expecting turnover growth in the upper half of the 3% to 5% range and core operating profit growth in the upper half of the 7% to 9% range. Core EPS growth is forecast in the lower half of that 7% to 9% range, reflecting additional interest expense following the Nuvalent acquisition. From what I see, running a quick comparison via Tickeron’s AI tools helped confirm the relative strength in the specialty segment.
Market Reaction and Investor Sentiment
GSK shares jumped as much as 6% in London trading on Tuesday, reaching 2,080 pence—their highest level since mid-April—before settling to a gain of roughly 3% to 4% by midday. In New York, American Depositary Shares (ADSs) rose approximately 3.35% in premarket trading to around $53.72.
The positive reaction reflected more than just the headline beat. Investors appeared to welcome the "Accelerate Growth" cost-savings programme, which analysts at Jefferies described as "surprisingly strong"—roughly double what the market had anticipated. The plan signals that management is serious about protecting margins through the patent cliff while simultaneously funding an ambitious pipeline expansion. The announcement that GSK now expects more than 20 Phase 3 trial starts in 2026, double its previous target of around 10, also reinforced confidence in the company's ability to replenish its portfolio with high-value assets.
Forward Outlook and Key Factors to Monitor
The earnings beat and strategic reset give GSK a stronger near-term narrative, but several factors will determine whether the momentum can be sustained.
First, execution on the cost-savings programme will be closely watched. The £1.9 billion annual savings target by 2029 comes with a £2.4 billion total price tag, most of which will be recognised in 2026 and 2027. Investors will want to see early evidence that the restructuring—which includes relocating the flagship R&D (research and development) centre from Stevenage to Cambridge and undisclosed job cuts—is proceeding on schedule and within budget without disrupting core operations.
Second, the pipeline acceleration must deliver. With more than 20 Phase 3 trials now planned across 18 indications spanning oncology, respiratory, hepatology, and vaccines, the next 12 to 18 months represent a critical readout period. Positive data from these trials would meaningfully de-risk the post-dolutegravir revenue outlook. Conversely, any high-profile failures could raise difficult questions about capital allocation.
Third, the trajectory of General Medicines remains a drag that cannot be ignored. The 9% decline in the quarter underscores that the erosion in legacy products is real and ongoing. How effectively the Specialty Medicines and Vaccines divisions can compensate—and whether the margin uplift from a better product mix proves durable—will be key to meeting the company's 2031 sales target of more than £40 billion.
Finally, the macro environment for pharmaceutical stocks remains relevant. The sector has benefited from defensive rotation in recent months, and GSK's roughly 6% year-to-date gain, while trailing the broader S&P 500, reflects steady rather than exuberant investor sentiment. The company's dividend yield of approximately 3.4% and a free cash flow yield of around 8% continue to offer a measure of downside support, but meaningful stock appreciation from here likely hinges on pipeline catalysts and evidence that the cost-savings programme is translating into improved operating leverage. One thing that stands out is how the strategic updates could influence sector peers, which I cross-checked briefly with Tickeron’s AI Screener.
Using AI Tools to Refine Pharma Research
In my own analysis of results like these, I often rely on Tickeron’s AI Screener to quickly filter pharmaceutical names by fundamentals, technical patterns, and performance metrics. It helps surface comparable opportunities and validate trends without hours of manual work, making the research process more efficient for investors focused on healthcare. Explore the AI Screener to see how it fits into your workflow.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
GSK's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for GSK turned positive on July 28, 2026. Looking at past instances where GSK's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 56 cases where GSK's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
GSK moved above its 50-day moving average on July 27, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GSK advanced for three days, in of 327 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 258 cases where GSK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GSK as a result. In of 71 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The 10-day moving average for GSK crossed bearishly below the 50-day moving average on July 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GSK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
GSK broke above its upper Bollinger Band on July 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 63, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. GSK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.392) is normal, around the industry mean (19.476). P/E Ratio (16.414) is within average values for comparable stocks, (29.740). GSK's Projected Growth (PEG Ratio) (105.200) is very high in comparison to the industry average of (10.091). Dividend Yield (0.035) settles around the average of (0.030) among similar stocks. P/S Ratio (2.381) is also within normal values, averaging (4.194).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of vaccines and other pharmaceutical products
Industry PharmaceuticalsMajor